This issue also includes some interesting articles: Abzu looks at the benefits of artificial intelligence (AI) and its uses in the pharma industry (
page 14), while Inizio considers the benefits and drawbacks of AI, especially in terms of diversity in synthetic patients (
page 13). Novartis considers the path to approval for paediatric medicines (
page 18) and Chiesi assesses the ways in which climate change can impact our lung health (
page 20). Finally, Alexion reflects on the health equity crises faced by patients with rare diseases (
page 16).